Harshita Singh

All stories by Harshita Singh

TCS Q4 review: Near-term growth to moderate, demand levers intact

TCS Q4 review: Near-term growth to moderate, demand levers intact

Rediff.com21 Apr 2023

The impact of the banking crisis in the US was visible in IT bellwether Tata Consultancy Services' (TCS) weak performance in the March quarter of fiscal 2023 (Q4FY23). The firm witnessed slower revenue growth in Q4FY23 and failed to meet its FY23 exit Ebit margin of 25 per cent as some clients, especially in the North American region, took to pausing projects and rising onsite costs offset utilisation gains. Sequentially, the company's revenue grew by just 0.6 per cent on a constant currency basis, which was one of the slowest paces in over 11 quarters.

Avoid paint stocks over the short-to-medium term

Avoid paint stocks over the short-to-medium term

Rediff.com20 Apr 2023

A likely turnaround in profitability margins in the March quarter (Q4FY23) will not be enough to lift the outlook for paint stocks due to volatile crude oil prices and rising competition in the sector, analysts say. Hence, they advise investors to avoid the sector over the short-to-medium term despite the heavy correction in the stocks since last year. Shares of Asian Paints, Berger Paints, Indigo Paints, Nerolac and Pidilite have shed 6-32 per cent over the last 6 months versus a 3 per cent rise in the benchmark Sensex.

Why analysts have turned cautious on Cipla

Why analysts have turned cautious on Cipla

Rediff.com10 Mar 2023

Analysts have turned cautious on Cipla, as the recently issued form 483 by the US FDA with eight observations to its Pithampur (Indore) plant is expected to delay the launch of the company's key generic - Advair - in the US. The Indore plant contributes around 5 per cent of Cipla's revenues, as per analysts' estimates. While the respiratory product, which is used to treat asthma, had cleared the pre-approval inspection of the regulator at the Indore unit; the final approval could be unlikely until the company clears the recent US FDA observations, analysts say.

'Long-term outlook for Infosys remains intact'

'Long-term outlook for Infosys remains intact'

Rediff.com23 Jan 2023

Strong Q3 brings Infosys comfort amid macro risks.

Rail stocks may chug along till Budget; book profit selectively: Analysts

Rail stocks may chug along till Budget; book profit selectively: Analysts

Rediff.com16 Dec 2022

The dream-run in railway stocks may soon run out of steam, caution analysts. The rally, which has lasted nearly a year, may meet time-wise correction post the Union Budget announcements as investors begin scalping profits. "There is going to be a build-up in expectations for the sector from the Union Budget, which is still two-odd months away.

Sula Vineyards: Should you subscribe to India's largest wine seller's IPO?

Sula Vineyards: Should you subscribe to India's largest wine seller's IPO?

Rediff.com13 Dec 2022

The initial public offer (IPO) of India's largest wine producer and seller Sula Vineyards (Sula) has opened for subscription and will close on Wednesday, December 14. The issue is entirely an offer-for-sale with 26.9 million shares on the offer, which could fetch Rs 915-960 crore to the promoters and selling shareholders. The price band is fixed at Rs 340-357. As per iPOWatch, the stock is currently commanding a grey market premium (GMP) of 11 per cent over the upper price band.

Are IT stocks a good contrarian bet from a one-year perspective?

Are IT stocks a good contrarian bet from a one-year perspective?

Rediff.com11 Oct 2022

The Nifty IT has been one of the worst-performing indices on the bourses this calendar year. Rising concerns of a potential global recession, which investors fear can dampen demand for export-facing domestic information technology (IT) giants, have sent the index down over 30 per cent on a year-to-date basis. By comparison, the Nifty50 Index has shed 2.8 per cent during the period, reveals data by ACE Equity.

Top 5 factors that may set market direction in H2 of 2022

Top 5 factors that may set market direction in H2 of 2022

Rediff.com8 Jul 2022

As markets complete the first half of the calendar year 2022 (CY22) with a fall of around 9 per cent, the interest-rate hike trajectory by global central banks, paired with the conundrum of inflation and growth, will move the needle for the market, observe experts. Here's a quick rundown on what they'll react to over the next six months.